49.05
price up icon0.08%   0.04
after-market アフターアワーズ: 48.26 -0.79 -1.61%
loading
前日終値:
$49.01
開ける:
$49
24時間の取引高:
932.94K
Relative Volume:
0.31
時価総額:
$7.16B
収益:
$10.73M
当期純損益:
$-455.74M
株価収益率:
-13.79
EPS:
-3.5569
ネットキャッシュフロー:
$-502.70M
1週間 パフォーマンス:
+1.91%
1か月 パフォーマンス:
+19.46%
6か月 パフォーマンス:
+71.98%
1年 パフォーマンス:
+5.01%
1日の値動き範囲:
Value
$48.25
$49.45
1週間の範囲:
Value
$46.09
$51.79
52週間の値動き範囲:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
名前
Avidity Biosciences Inc
Name
セクター
Healthcare (1139)
Name
電話
858-401-7900
Name
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
391
Name
Twitter
Name
次回の収益日
2024-12-07
Name
最新のSEC提出書
Name
RNA's Discussions on Twitter

RNA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
49.05 7.15B 10.73M -455.74M -502.70M -3.5569
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.27 107.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
474.00 64.39B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
579.34 61.13B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
834.75 52.30B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.31 35.49B 398.11M -1.03B -868.57M -5.7032

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-17 開始されました Roth Capital Buy
2025-07-10 再開されました Goldman Buy
2025-06-24 開始されました Bernstein Outperform
2025-06-17 開始されました Wolfe Research Outperform
2025-06-11 開始されました Raymond James Strong Buy
2025-03-13 開始されました Citigroup Buy
2025-03-12 開始されました BMO Capital Markets Outperform
2025-03-07 開始されました Scotiabank Sector Outperform
2024-12-20 開始されました H.C. Wainwright Buy
2024-11-26 開始されました RBC Capital Mkts Outperform
2024-09-24 開始されました Goldman Buy
2024-08-28 開始されました Barclays Overweight
2024-05-03 開始されました BofA Securities Buy
2024-03-14 開始されました Cantor Fitzgerald Overweight
2023-05-22 アップグレード Evercore ISI In-line → Outperform
2023-03-31 ダウングレード Evercore ISI Outperform → In-line
2022-07-20 開始されました Chardan Capital Markets Buy
2022-07-12 開始されました Raymond James Strong Buy
2021-09-07 開始されました Evercore ISI Outperform
2021-06-17 開始されました Needham Buy
2021-04-26 再開されました Credit Suisse Outperform
2020-07-07 開始されました Cowen Outperform
2020-07-07 開始されました Credit Suisse Outperform
2020-07-07 開始されました SVB Leerink Outperform
2020-07-07 開始されました Wells Fargo Overweight
すべてを表示

Avidity Biosciences Inc (RNA) 最新ニュース

pulisher
02:04 AM

Ranking Avidity Biosciences Inc. among high performing stocks via toolsDip Buying & Fast Gain Stock Tips - newser.com

02:04 AM
pulisher
Oct 20, 2025

Avidity Biosciences Inc. stock daily chart insightsMarket Volume Report & Technical Analysis for Trade Confirmation - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Can Avidity Biosciences Inc. stock beat market expectations this quarterDividend Hike & Risk Controlled Daily Trade Plans - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

How Avidity Biosciences Inc. stock compares to growth peersTrade Ideas & Verified Technical Trade Signals - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

Using R and stats models for Avidity Biosciences Inc. forecastingDollar Strength & Growth Focused Investment Plans - newser.com

Oct 19, 2025
pulisher
Oct 19, 2025

Avidity Biosciences Inc. stock trendline breakdownJuly 2025 Opening Moves & Stock Market Timing Techniques - newser.com

Oct 19, 2025
pulisher
Oct 18, 2025

Is Avidity Biosciences Inc. stock a top pick in earnings seasonShare Buyback & Low Drawdown Investment Strategies - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Aug Closing: Can Avidity Biosciences Inc. stock hit record highs again - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Aug EndMonth: Can Avidity Biosciences Inc. stock hit record highs againPortfolio Update Report & Reliable Price Action Trade Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Is Avidity Biosciences Inc. stock a defensive play in 2025Market Activity Report & High Accuracy Investment Entry Signals - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

Avidity Biosciences Insider Sold Shares Worth $1,003,058, According to a Recent SEC Filing - MarketScreener

Oct 17, 2025
pulisher
Oct 17, 2025

Avidity Biosciences Executive Sells 20,000 Shares - TradingView

Oct 17, 2025
pulisher
Oct 17, 2025

Avidity Biosciences Form 4: 20,000 options exercised at $22.34 - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

How Avidity Biosciences Inc. stock performs in weak economyPortfolio Update Report & Low Drawdown Investment Strategies - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Facioscapulohumeral Muscular Dystrophy Market Analysis Report 2025-2035: Innovations from Leading Players Such as Avidity Biosciences, F. Hoffman-La Roche, Epicrispr, and Fulcrum Fuel ExpansionResearchAndMarkets.com - The AI Journal

Oct 17, 2025
pulisher
Oct 17, 2025

Will FDA Feedback and Del-Zota BLA Timeline Shift Redefine Avidity Biosciences' (RNA) Late-Stage Pipeline? - Yahoo Finance

Oct 17, 2025
pulisher
Oct 16, 2025

Will a bounce in Avidity Biosciences Inc. offer an exitTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com

Oct 16, 2025
pulisher
Oct 16, 2025

Is Avidity Biosciences Inc a good long term investmentRisk Management Strategies & Tap Into the Fastest-Growing Companies - earlytimes.in

Oct 16, 2025
pulisher
Oct 16, 2025

Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

What momentum shifts mean for Avidity Biosciences Inc.Insider Buying & Reliable Breakout Forecasts - newser.com

Oct 16, 2025
pulisher
Oct 16, 2025

Oct 21 panel: Avidity Biosciences to speak at Chardan Conference; webcast available 11:00 PT - Stock Titan

Oct 16, 2025
pulisher
Oct 16, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - Sahm

Oct 16, 2025
pulisher
Oct 15, 2025

Sector ETF performance correlation with Avidity Biosciences Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Forecasting Avidity Biosciences Inc. price range with options data2025 EndofYear Setup & High Return Stock Watch Alerts - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Avidity Biosciences Inc (RNA) Technical Analysis - TipRanks

Oct 14, 2025
pulisher
Oct 14, 2025

What Makes Avidity Biosciences (RNA) an Investment Choice? - MSN

Oct 14, 2025
pulisher
Oct 14, 2025

[8-K] – Avidity Biosciences, Inc. (RNA) (CIK 0001599901) | RNA SEC FilingForm 8-K - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Avidity Biosciences Delays Biologics License Application - TipRanks

Oct 14, 2025
pulisher
Oct 14, 2025

Avidity Biosciences Updates BLA Submission Timeline for Del-Zota - TradingView

Oct 14, 2025
pulisher
Oct 14, 2025

Avidity updates FDA filing plan; del-zota BLA now expected Q1 2026 - Stock Titan

Oct 14, 2025
pulisher
Oct 13, 2025

Avidity Biosciences delays DMD drug submission to Q1 2026 By Investing.com - Investing.com Nigeria

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 - Investing News Network

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences announces positive pre-BLA meeting with US FDA for del-zota in DMD44 - MarketScreener

Oct 13, 2025

Avidity Biosciences Inc (RNA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Avidity Biosciences Inc (RNA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
McCarthy Teresa
Chief Human Resources Officer
Oct 15 '25
Sale
50.15
20,000
1,003,058
97,130
Mosbrooker Eric
Chief Commercial Officer
Oct 03 '25
Option Exercise
9.05
6,562
59,386
61,562
Mosbrooker Eric
Chief Commercial Officer
Oct 03 '25
Sale
45.38
6,562
297,771
55,000
Hughes Steven George
Chief Medical Officer
Sep 22 '25
Option Exercise
10.16
2,208
22,433
41,075
Hughes Steven George
Chief Medical Officer
Sep 22 '25
Sale
40.58
2,208
89,601
38,867
McCarthy Teresa
Chief Human Resources Officer
Sep 15 '25
Option Exercise
22.34
15,000
335,100
112,130
McCarthy Teresa
Chief Human Resources Officer
Sep 15 '25
Sale
41.41
15,000
621,142
97,130
Hughes Steven George
Chief Medical Officer
Sep 15 '25
Option Exercise
6.57
1,542
10,131
40,409
Hughes Steven George
Chief Medical Officer
Sep 15 '25
Sale
45.41
1,542
70,022
38,867
Flanagan W. Michael
Chief Scientific Officer
Sep 11 '25
Option Exercise
14.22
20,000
284,400
100,195
$37.48
price up icon 2.32%
$87.30
price up icon 1.31%
$30.13
price down icon 1.34%
$106.89
price down icon 0.98%
biotechnology ONC
$315.74
price down icon 0.90%
$165.31
price down icon 1.55%
大文字化:     |  ボリューム (24 時間):